AFM28
Phase 1Terminated 2 views this week 0 watching💤 Quiet
Interest: 11/100
11
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia
Trial Timeline
Mar 21, 2023 → Jun 13, 2025
NCT ID
NCT05817058About AFM28
AFM28 is a phase 1 stage product being developed by Affimed for Acute Myeloid Leukemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT05817058. Target conditions include Acute Myeloid Leukemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05817058 | Phase 1 | Terminated |
Competing Products
20 competing products in Acute Myeloid Leukemia